Abstract. The G protein-coupled receptors (GPCRs) form the largest and the most versatile superfamily that share a seven-transmembrane-spanning architecture. GPCR-signaling is involved in vision, taste, olfaction, sympathetic/parasympathetic nervous functions, metabolism, and immune regulation, indicating that GPCRs are extremely important therapeutic targets for various diseases. Cellular dielectric spectroscopy (CDS) is a novel technology that employs a label-free, real-time and cell-based assay approach for the comprehensive pharmacological evaluation of cells that exogenously or endogenously express GPCRs. Among the biosensors that use CDS technology, the CellKey TM system not only detects the activation of GPCRs but also distinguishes between signals through different subtypes of the Ga protein (Gs, Gi/o, and Gq). In this review, we discuss the traditional assays and then introduce the principles by which the CellKey TM system evaluates GPCR activation, followed by a perspective on the advantages and future prospects of this system.
Introduction
The G protein-coupled receptors (GPCRs) are the largest and the most versatile superfamily among cell surface receptors (1) . The human genome encodes more than 800 GPCRs, which account for approximately 2% of the human genome (2, 3) . Members of the GPCR family share structural similarities including a seven-transmembrane-spanning domain linked by an N-terminal extracellular domain, C-terminal intracellular domain, three extracellular loops, and three intracellular loops (4) .
Even so, different GPCRs interact with different types of ligands, including photons, ions, biogenic amines, peptide and non-peptide neurotransmitters, hormones, growth factors, and lipids (3) . Consequently, GPCR signaling is involved in vision, taste, olfaction, sympathetic and parasympathetic nervous functions, metabolism, and immune regulation, indicating that GPCRs are very important therapeutic targets for various diseases (4) . Indeed, several researchers over the world have received the Nobel Prize for their research in the field of GPCRs (5) ( Table 1 ). It is evident that such significant and novel discoveries of GPCRs will potentially facilitate the development of novel therapeutic drugs. In fact, several pharmaceutical companies have developed medicines that can modulate GPCR signaling pathways, which are estimated to be 30% in the market (1, 3) . Impedance Assay for GPCRs Using CellKey TM Multiple lines of evidence demonstrate that the agonistbound GPCRs induce a conformational rearrangement of these receptors and subsequently activate the heterotrimeric G proteins, composed of a-, b-, and g-subunits (3, 4) . The conformational change of the ligand-bound GPCRs catalyzes the exchange of guanidine diphosphate (GDP) for guanidine triphosphate (GTP) on the a-subunit (Ga) of the G proteins, thereby dissociating Ga from the dimeric b-and g-subunits (Gbg) (4) . Based on the amino acid sequence homologies of their Ga subunit, heterotrimeric G proteins are classified into four families: Ga s (Gs), Ga i (Gi), Ga q (Gq), and Ga 12 (G12) (6) . In addition, the functions of Ga o (Go) proteins are similar to those of Gi, so that both the Gi and Go proteins belong to the Gi/o category of the G-protein families (4) . Upon activation of GPCRs, each Ga subunit stimulates and integrates a distinct signaling pathway. Despite extensive studies, a comprehensive characterization of the G proteincoupling profile of GPCRs remains incomplete: for example, some GPCRs can couple only to a single type of G protein (e.g., Gs or Gq), whereas many GPCRs couple to a broader range of G protein families such as Gs/Gi, Gi/Gq, or Gq/G12 (6) .
In addition to the classical roles of GPCRs, the concept of homodimeric or heterodimeric GPCRs has gained acceptance in the last few decades (3, 7) . GPCRs exist in a dynamic equilibrium between a monomeric and dimeric state, and their heterodimerization affects pharmacological and cellular signaling responses differently compared to when only the receptor subtypes are individually expressed (7) . These novel findings were impossible to discover without the development of sophisticated assay for GPCRs (3) . In this review, we provide a historical account of the representative GPCRs assay and then introduce a novel, recently developed "biosensor-based cellular assay".
Traditional assays for the GPCRs
The classical GPCR assays are classified into two categories, ligand-binding assay and functional assay. In the late 1960s and early 1970s, GPCR research began with the development of assays that used radioisotopes (1) . Subsequently, several assays were developed and improved with time (3). This review discusses some of these frequently used assays.
Ligand-binding assay
GPCRs are activated when the agonist binds to its receptor. The ligand-binding assay is used to assess whether a target compound binds to a cell surface receptor. In the classical method, the binding capacity of the target compound that competes with the radiolabeled ligand for a common receptor is measured (1, 3) . Recently, radiolabeled ligands have been replaced with fluorescent ligands in this competition binding assay (3). Structural studies of GPCRs to reveal the GPCR signal transduction from extracellular information into intracellular chemical messages
Functional assay
The functional assays for GPCRs are based on the detection of receptor activation and signaling. Among the Ga protein subtypes, several assays for Gs-, Gq-, and Gi/o-protein-coupled receptors are well known.
Assay for the activation of Gs protein-coupled receptors
Gs protein activates adenylyl cyclase (AC) that causes an increase in the intracellular concentration of cyclic adenosine 3′,5′-monophosphate (cAMP) produced from adenosine 5′-triphosphate (ATP), thereby activating protein kinase A (PKA) (6) (Fig. 1) . Thus, the levels of cytosolic cAMP is routinely determined as a measure of the activation of the Gs protein-coupled receptors (1, 3) . This assay was developed in the 1970s and mostly utilizes the enzyme immunoassay (EIA) using whole cell or tissue lysates (1, 3) . Recent technological advances have facilitated the real-time detection of changes in the intracellular cAMP level without the cell lysis step (8, 9).
Assay for the activation of Gq protein-coupled receptors
Gq proteins activate phospholipase C (PLC), which catalyzes the production of diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP 3 ) from phosphatidylinositol 4,5-bisphosphate (PIP 2 ) (3, 6) ( Besides the fluorescent probes, genetically encoded Ca 2+ sensors (GECSs) are also used for measuring [Ca 2+ ] i (11, 12) . GECSs are divided into two classes: luminescent and fluorescent sensors. These are transfected into target cells and tissues and are suitable for the measurement of [Ca 2+ ] i for a relatively longer duration (11, 13) . In our laboratory, G-CaMP, a fluorescent sensor that is a protein complex composed of mutated green-fluorescent protein (GFP), calmodulin (CaM), and Ca 2+ /CaMbinding peptide, was used for the visualization of changes in [Ca 2+ ] i (14) . G-CaMP (G-CaMP1) was originally established by J. Nakai et al. in 2001 (15) . A series of G-CaMPs were developed to improve Ca 2+ -binding affinity, fluorescence sensitivity, and to express some particular regions such as just under the plasma members (11 -13, 15, 16) . Different types of G-CaMPs (G-CaMP1-8) have been developed and are used in different experimental conditions depending on the kinds of cells/tissues or fluorescence sensitivity for detecting [Ca 2+ ] i levels in the cells/tissues (11 -13, 15, 16).
Assay for the activation of Gi/o protein-coupled receptors
Gi/o proteins inhibit the activity of AC and decrease the intracellular cAMP levels (6) (Fig. 1) . The activity of Gi/o protein-coupled receptor can be evaluated by the inhibition of cAMP production, which was previously activated by an AC activator or Gs protein-activating receptors (17) . In this method, the activity of Gi/o proteincoupled receptor cannot be measured directly. To circumvent this problem, the GTPgS binding assay is commonly used for detecting the activity of Gi/o proteincoupled receptor (18) . As shown in Fig. 1 , the activation of Ga proteins including Gi/o protein is induced by the exchange of GDP for GTP, indicating that the binding of GTP to Ga protein is a key step in the activation of GPCRs (18) . The GTPgS binding assay was developed in the 1980s (19) and has been widely used in the drug screening process (3). This assay requires preparation of the plasma membrane fraction from GPCR-expressing cells or tissues as well as labeled GTP analogues such as GTPgS ([ 35 S]-GTPgS or Eu-GTPgS) that cannot be readily hydrolyzed (17, 18) .
A novel assay for GPCRs using cellular dielectric spectroscopy
Cellular dielectric spectroscopy (CDS) is a novel technology that utilizes a label-free, real-time and cell-based assay approach and enables comprehensive pharmacological evaluation of cells that exogenously or endogenously express receptors (20, 21) . This technology is universal and allows the measurement of multiple types of receptors, including GPCRs, tyrosine kinase receptors, and nuclear receptors on the same platform without any modification of the cells (20, 21) . CDS is classified into two types, an optical-based biosensor and an electrical impedance-based biosensor (3). The CellKey TM system (MDS Sciex, Ontario, Canada), one of the electrical impedance-based biosensors, is specifically tailored to GPCR detection and produces response profiles that are consistent across a wide range of assay conditions and can distinguish signals between Gs, Gi/o, and Gq (20).
Principles of the CellKey
TM system The CellKey TM assay detects the changes in impedance (DZ) of a cell layer, defined by the ratio of the voltage Impedance Assay for GPCRs Using CellKey TM (applied by the CellKey TM instrument) to the current (measured by the CellKey TM instrument), as described by Ohm's law (Z = V/I). Cells are seeded onto a standard CellKey TM 96-well microplate that contains electrodes at the bottom of the wells (Fig. 2) . Small voltages are applied to these electrodes every 2 or 10 s and the impedance changes according to the changes in cell adherence, cell shape and volume, cell-to-cell interaction, and other cellular alterations (Figs. 1 and 2 ). Many reports indicated that cell signaling induced by GPCR activation can induce changes in morphology, and there are well-established links between Gs, Gi, and Gq signaling pathways (21 -24) . The activation of GPCR, therefore, changes the impedance, which can be interpreted as the differences of GPCR activation. Figure 3 illustrates the different patterns of DZ caused by each ligand for specific types of GPCRs (Gq, Gs, and Gi/o). Among the 5 muscarinic acetylcholine receptors (M1 -M5), M1, M3, and M5 acetylcholine receptors couple with the Gq protein, whereas M2 and M4 acetylcholine receptors coupled with the Gi/o protein (25, 26) . In human embryonic kidney 293 (HEK293) cells, M3 is endogenously expressed at a low level (25, 26) . We therefore stimulated HEK293 cells with the vehicle or acetylcholine (10 mM). Compared to the vehicle, acetylcholine induced a rapid decrease followed by a gradual increase in DZ (Fig. 3A) . In addition, we used the b-adrenergic receptor as the Gs protein-coupled receptor. In rat C6 glioma cells that endogenously express both b1-and b2-adrenergic receptors (27) , treatment with isoproterenol (100 nM), an agonist of the badrenergic receptor, induced a decrease in DZ (Fig. 3B ). This decrease was significantly suppressed by pretereatment with propranolol, an inhibitor of the b-adrenergic receptor (Fig. 4A ) and with cholera toxin (CTX), an inhibitor of the activated Gs protein (Fig. 4B) . These data suggest that isoproterenol induces a decrease in DZ via activation of b-adrenergic receptor and Gs protein. Figure 3C shows that SNC80 (10 nM), a selective d-opioid receptor (DOR) agonist, induces an increase in DZ in HEK293 cells that exogenously express DOR. The increase in DZ evoked by SNC80 was suppressed by naltrindole (NTI) and pertussis toxin (PTX), inhibitors of DOR and Gi/o protein activation, respectively (Fig. 4: C and D) . These data suggest that SNC80 activates Gi/o protein through DOR, thereby inducing an increase in DZ. Figure 3 also demonstrates that the CellKey TM system can detect the activation of endogenous GPCRs, whose expression levels are lower than those of exogenous GPCRs. Moreover, Scott and Peters (21) reported that the CellKey TM system is highly sensitive compared to traditional assays, such as the GTPgS binding assay, cAMP assay, and Ca 2+ imaging assay. Taken together, these results affirm that the CellKey TM system can be used to generate pharmacologically high-quality data.
Evaluation of GPCR activation using the CellKey TM system

Advantages of the CellKey
TM assay system Compared to the classical assays, the CellKey TM system has the following advantages. First, this system can detect signaling induced by various combinations of Ga subunits simultaneously, whereas traditional assays detect only single Ga subunits. While some GPCRs can couple only to a single type of G protein (e.g., Gs or Gi/o), many GPCRs often couple to a broader range of G-protein families such as Gs/Gi or Gi/Gq (6). In HEK293 cells expressing m-opioid receptor (MOR), DZ induced by morphine, an MOR agonist, were inhibited not only by PTX (an inhibitor of Gi/o protein activation) but also by Y-27632 [an inhibitor of Rhoassociated coiled-coil forming protein serine/threonine kinase (ROCK)], which is activated by G12 protein activation] (data not shown). Thus, the CellKey TM system is a simple assay in which a single assay platform can detect multiple types of GPCR signaling. In addition, the CellKey TM system does not require labeled ligands and is designed with usage of 96-or 384-well plates. Thus, simplified assay design, minimal artifacts, and shortened assay time, contribute to higher throughput of the CellKey TM system. Second, the CellKey TM system is able to distinguish between each of the three major G protein-dependent pathways (Gs, Gq, and Gi/o) with different kinetic DZ. This characteristic can be attributed only to the CellKey TM system among all the CDS-based instruments (20, 21) .
Third, the CellKey TM assay is particularly superior for the activation of Gi/o protein-coupled receptors compared to traditional assays, such as GTPgS binding or cytosolic cAMP assays, among the three major types of G protein-dependent signaling (Gs, Gq, and Gi/o) (17) . The GTPgS binding assay requires radioactive substances that are a safety concern. In the cAMP assay, stimulation of AC with forskolin is required to measure the decrease in cytosolic cAMP induced by the activation of Gi/o protein-coupled receptor, indicating that we evaluated a reversal effects of Gi/o protein-coupled receptor agonist against increase in cytosolic cAMP induced by forskolin. This assay cannot actually detect the activity of the Gi/o protein-coupled receptor. On the other hand, the CellKey TM assay can detect the direct activation of the Gi/o protein-coupled receptors using a non-labeled, whole-cell, and real-time approach.
Lastly, the CellKey TM system has similar or higher sensitivity than a traditional system using label-based assays such as the GTPgS, Ca 2+ flux, and cAMP assays. They demonstrated that EC 50 values between CellKey TM and Ca 2+ or cAMP were almost the same level. In Gi-coupled receptor, however, the EC 50 value in the CellKey TM system was three-to ten-fold more potent than that in the GTPgS assay (19).
Future Prospects of the CellKey
TM system In this review, we have introduced the basic features of the CellKey TM system. However, the features of the CellKey TM system are not limited to either a simple operation or a high-throughput analysis. We are now developing novel assays for making new discoveries.
Evaluation of G protein-independent signaling pathways
Recent studies have indicated that there are G proteinindependent signaling pathways, one of which is related to b-arrestin, a cytosolic signal transducing protein (3). b-Arrestin binds to ligand-activated GPCRs, which are phosphorylated by G protein-coupled receptor kinases (GRKs) to induce desensitization. The receptor-b-arrestin complex then loses the ability to couple with the G protein, suggesting that GRKs and b-arrestin play an important role in GPCR desensitization by preventing the coupling with G protein (3, 28, 29) . In addition, b-arrestin facilitates agonist-induced internalization via clathrin-coated pits (28, 29) . b-Arrestin-mediated internalization is required for the phosphorylated receptors to restore the responsiveness of GPCR-mediated signaling (28) . Thus, b-arrestin has two roles, desensitization and resensitization. The acidic conditions in the endosomes induce conformational changes in the receptor and enhance dephosphorylation by G protein-coupled receptor phosphatases (GRP) (28) . The dephosphorylated receptor then returns to the cell surface and is ready for responding to a new stimulus. This is termed "recycling of the receptor" (28) .
Many GPCRs are known to undergo b-arrestinmediated receptor internalization via an actin cytoskeletondependent process (21, 30) . CDS biosensors containing CellKey TM system can measure changes in the actin cytoskeleton (20, 21) , suggesting that this system detects b-arrestin-mediated receptor internalization or b-arrestindependent cell signaling. Consequently, we are trying to establish assays for the evaluation of b-arrestindependent signaling using so-called "biased" ligands, which are defined as agonists that induce G protein-or b-arrestin-biased signaling (29).
Evaluation of GPCR heterodimerization
In the last few decades, the concept of GPCRs forming homodimers and heterodimers with other GPCRs has gradually gained acceptance. GPCRs exist in a dynamic equilibrium between a monomeric and dimeric state (3, 7) . GPCR heterodimerization is known to alter ligand binding, cellular signaling responses, and internalization in comparison to GPCR monomers (7) . The greatest challenge involved in conducting studies on GPCR heterodimers is the lack of appropriate assays for detecting the functional alteration of GPCRs. Consequently, high-throughput analysis of GPCR heterodimers has never been accomplished (7) . The CellKey TM system detects the activation of GPCRs as whole-cell responses, which are mediated by various cell signaling modulators. Thus, it is possible that the CellKey TM system may enable the detection of the GPCR heterodimer-dependent signaling in a high-throughput mode.
Conclusions
This review discusses traditional assays for the detection of GPCRs coupled to Gs, Gq, and Gi/o proteins, as well as the state-of-the-art CellKey TM system. The CellKey TM system can measure the activity of GPCRs in one platform with the same or even higher sensitivity as the traditional assays. In addition, this system employs a non-label, whole-cell, real-time, and high-throughput approach, indicating that it is simpler than the traditional assays. The CellKey TM system is expected to contribute to novel insights in GPCR studies, such as the establishment and validation of concepts of biased ligands or heterodimer theory, which may facilitate the rational design of novel therapeutic drugs. However, it is necessary for developing this assay further to determine how impedance induced by the activation of each GPCR changes or which types of cell signaling are important for changes in impedance. We are actively working to overcome the challenging issues. We expect that establishment of new assays and technology using the CellKey TM system will lead to innovative drug development.
